Madrigal Pharmaceuticals Q2 revenue rises 71% on Rezdiffra demand

Madrigal Pharmaceuticals

30/07/2026 12:15

Overview
U.S. MASH drugmaker's Q2 revenue rose 71% yr/yr on strong Rezdiffra demand
Company's Q2 net loss widened as operating expenses increased for commercial and R&D activities
Madrigal strengthened IP portfolio with 3 new resmetirom patents and advanced MGL-2086 to Phase 1

Outlook
Company did not provide specific financial guidance for the current or upcoming periods

Result Drivers
REZDIFFRA DEMAND - Revenue growth attributed to increased U.S. demand for Rezdiffra, with more than 49,000 patients on therapy as of June 30
COMMERCIAL INVESTMENT - Higher operating expenses driven by increased spending on Rezdiffra commercial activities, including field force expansion and marketing
ROYALTY AND INVENTORY COSTS - Cost of sales rose due to higher royalties payable to Roche and inventory write-downs linked to increased Rezdiffra sales

Company press release: ID:nGNX1s1g7F

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
 
$364.25 mln
 
Q2 Loss Per Share
 
$1.99
 
Q2 Net Loss
 
$57.94 mln
 
Q2 Operating Expenses
 
$420.56 mln
 
Q2 Operating Income
 
-$56.31 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Madrigal Pharmaceuticals Inc is $659.50, about 20.6% above its July 29 closing price of $546.88

Reuters Recommended Reads
July 30 - Agios Q2 revenue jumps on US commercial launch of AQVESME
July 29 - Viking Therapeutics reports Q2 milder-than-expected net loss as obesity trials advance
July 29 - Biogen beats quarterly estimates as newer drugs drive growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)